Pexelizumab

Drug Profile

Pexelizumab

Alternative Names: 5G1.1-SC; Anti-C5 monoclonal antibody 5G1-1-SC; h5G1.1-scFV; Monoclonal antibody 5G1.1-SC; Short-acting monoclonal antibody 5G1.1

Latest Information Update: 07 May 2007

Price : $50

At a glance

  • Originator Stanford University
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Myocardial infarction; Reperfusion injury

Most Recent Events

  • 07 May 2007 Proctor & Gamble terminates its licence for pexelizumab worldwide
  • 28 Jun 2006 Interim results from a phase III clinical trial (APEX-AMI) in patients with myocardial infarction have been added to the Ischaemic Heart Disease therapeutic trials section
  • 09 Aug 2005 Alexion Pharmaceuticals and Procter & Gamble have completed enrollment in the PRIMO-CABG2 trial
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top